

FINANCIAL SUPERVISION AUTHORITY

Current report No. 40 /2018

Date prepared: 08/06/2018

Abbreviated name of the issuer:

MABION S.A.

Subject

Announcement of candidacy for the independent Member of the Supervisory Board of the Company

Legal basis

Art. 56 section 1 point 2 of the Act on Public Offering – current and periodic information

Content of the report:

The Board of Mabion S.A. – ”the Company” – hereby informs that due to the planned agenda of the Ordinary General Meeting of Shareholders of the Company convened on 28th June 2018, which schedules passing resolutions concerning changes within the membership of the Supervisory Board, on 7th June 2018 it received from the shareholder of the Company – Europejski Bank Odbudowy i Rozwoju – an announcement of candidacy of Mr. Dirk Kreder for the position of the independent Member of the Supervisory Board of the Company.

Information about his education, qualifications and previously held positions, as well as description of professional experience of the candidate, is presented below.

Mr. Dirk Kreder has vast experience and an extensive business network in pharmaceutical and biotechnological businesses, strong business awareness and experience in management of small and large companies in pharmaceutical business in Europe and in the USA. He contributed to development and registration of biosimilar and generic medicinal drugs in the USA, EU, Canada, Australia, Japan and on other markets; he has over 10 years of experience in development and commercialization of more than 20 medicinal drugs.

PROFESSIONAL EXPERIENCE

Anteris group – Munich, Germany – 2014–present

- He founded, built and continues to manage a number of companies – at present: three, founding of the fourth one: in progress – within the Anteris group, in order to build a complex and complete model of support for development and registration of biosimilar medicinal drugs all around the world;
- At present 20 employees and consultants, income expected in 2018: around EUR 3,7 million; the Company is profitable;
- Since its founding, Anteris is a part of more than 20 programs of development and registration in 7 countries;
- Internationally recognized expert in development and registration of biosimilar medicinal drugs, regularly invited to participate in conferences and workshops as a presenter.

microDimensions GmbH – Munich, Germany – 2016–present

Member of the Advisory Council – advisor in terms of registration and possibility of commercialization of diagnostic medical devices.

Sandoz – part of the Novartis group – Munich, Germany – 2007-2014

Alliance Manager and Program Leader for biosimilar and generic medicinal drugs market

- Manager of Sandoz teams working in 4 production plants in order to develop and register priority products;
- Global program, which led to registration of the first biosimilar drug on regulated markets – Omnitrope®;

- Lead to completing documentation ready for the process of registration in less than one year _ complex generic medicinal drug of the market value of USD 3,5 billion in the USA_;
- Responsible for all aspects connected with development, registration, budgeting, supply chain, as well as other departments and companies;
- Negotiating and implementing agreements with partners and suppliers.

Novartis Pharma AG – Basel, Switzerland – 2004-2007

Global Decision Support Manager

- Manager of the Global Decision Support Team and Portfolio Management Team, which deal with improvement of the leading projects of Novartis and management of resources and developmental processes;
- Supporting Key Customers and supervising developmental projects concerning infectious diseases for Novartis KK, Tokyo.

Abgenix, Inc. _present: Amgen_ – Fremont, California – 2001-2004

Director of the Bioinformatics Department

- Created a team consisting of bioinformatics specialists and software engineers _ eight permanent employees and four consultants _ whose aim is to create a platform for development of antibody products;
- Supervised research and acted as a project manager for a number of antibody products development programs;
- Responsible for maintaining strategic relations with departments of Pharma and Biotech;
- Contributed to Panitumumab Program_Vectibix_ created in cooperation with Amgen.

Hoffmann-LaRoche _Roche Bioscience_ Palo Alto, California – 1999-2001

Research worker, Bioinformatics Department

- His main responsibilities were: setting goals and technological development in cooperation with Incyte Geonomics;
- Initiated and supervised several programs in cooperation with American and international companies.

Maxygen, Inc. – Redwood, California – 1998-1999

Post-doctoral internship

- Created and managed the "directed evolution" project for the state program connected with the system of defense.

EDUCATION:

International Executive MBA – Maastricht, Warsaw, Leipzig, Nantes, Aix-en-Provence, Barcelona – 2011-2013

Euro* MBA

- International program in six business schools in Europe, graduated with distinction.

American Management Association Chicago, New York, Atlanta 2001-2003

AMA's Mini-MBA and Project Management

- Syllabus included Finance, Accountancy, Strategy Building, Marketing, Management and Project Management.

University of California Santa Cruz Silicon Valley Extension 2001 – 2002

Certificate in Bioinformatics

University of Stuttgart and University of Kiel – Stuttgart and Kiel, Germany 1994-1997

PhD degree in Bioinformatics and Immunology

- Graduated with distinction.
- topic of the PhD dissertation: Analysis of the in vivo function of the TNFR55 associated protein FAN by generation of fan deficient mice.

California State University – Arcata and Chico, California 1991
International Exchange Program
- Friedrich-Ebert-Stiftung Student Association, Bonn, Germany.

OTHER PROFESSIONAL EXPERIENCE:

Venture Capital Firm – Palo Alto, California – 2000 - 2001
- Consulting services in venture capital sector and management consulting sector.

Biotech Start-Up Mountain View, California – 2000
- Created a reserved relational database for tissue markers.

Innovation Strategy and Design Firm Palo Alto, California – 1999-2000
- Participation in consultations concerning functionality of a graphic interface created for the Customer's needs of the global leader in genomics business.

Mr. Dirk Kreder hereby declares that he agrees for his candidacy for the position of the Member of the Supervisory Board of Mabion S.A., he meets the independence requirements for the position of the independent member of the supervisory board in the meaning of the Commission Recommendation of 15th February 2005 on the role of non-executive or supervisory directors of listed companies and on the committees of the (supervisory) board, he is not involved in a competitive company as a partner in a civil law company or a partnership or as member of a governing body of a capital company or in any other competitive legal entity as a member of its governing body and that he is not entered in the Register of Insolvent Debtors, which is conducted on the basis of the Act on the National Court Register.